Subject selection [Design Issues]

posted by nobody – 2014-10-23 19:53 (4263 d 00:33 ago) – Posting: # 13778
Views: 27,949

Let's talk about sex, not gender (which is a sociolgical combat term, implying that all differences between men an women are made up by education. Biology and sex hormones are all secondary. Sounds strange, but...)

So what you are looking for is examples of differences between formulations (not active compounds) in absorption between women and men. Will be hard to find, I guess. Maybe the reason why FDA started with women in BE trials, as there is no sound scientific basis to exclude them.

But we started with genetic polymorphisms. If nothing is published on that: GREAT! Then let's start with studying intraindividual variability (repeated dosing) for different CYP geno/phenotypes. Should be worth going for and has not been done (published) so far! :-D

If you don't see differences on intraindividual variability it should not be worth going for selected geno/phenotypes for this CYP in the future, I guess. Otherwise...

PS: Another term for "difference in geno/phenotype" might be "race". There are compounds with distinct differences in BA depending on race. In principle higher BA should correspond to lower variability (both intra- and interindividual, I guess). Might be worth having a look at in the literature

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
162 visitors (0 registered, 162 guests [including 27 identified bots]).
Forum time: 20:26 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5